Keyphrases
Confidence Interval
70%
European Union
64%
Hodgkin Lymphoma
58%
Population-based Cohort Study
57%
Europe
46%
Meta-analysis
43%
European Countries
39%
Netherlands
39%
Direct Oral Anticoagulants
37%
Medicinal Products
37%
Incidence Rate
37%
Breast Cancer Risk
36%
Cancer Risk
35%
Marketing Authorization
35%
Denmark
34%
Insulin
34%
United States
33%
Breast Cancer
32%
QT Prolongation
32%
Summary of Product Characteristics (SmPC)
29%
Pharmacoepidemiology
29%
Type 2 Diabetes Mellitus (T2DM)
28%
Systematic Meta-analysis
28%
Insulin Analogues
26%
Hazard Ratio
25%
Non-valvular Atrial Fibrillation
25%
Drug Utilization Study
25%
European Medicines Agency
25%
Pharmacovigilance
25%
Clinical Practice Research Datalink
24%
Antidepressants
24%
Ankylosing Spondylitis
22%
Odds Ratio
21%
United Kingdom
20%
Radiotherapy
20%
Selective Serotonin Reuptake Inhibitors
20%
Standardized Incidence Ratio
19%
Cancer Inpatients
19%
Canada
19%
Adverse Drug Reaction
19%
Adverse Drug Event Reporting
18%
Ventricular Arrhythmia
18%
Bladder Cancer
18%
Drug Development
18%
Cancer Incidence
18%
Dabigatran
17%
Adverse Events
17%
Multi-database
17%
Major Bleeding
17%
Gene Therapy
17%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Pharmacovigilance
53%
Malignant Neoplasm
49%
Adverse Drug Reaction
46%
Breast Cancer
41%
Hodgkin Disease
41%
Direct Oral Anticoagulant
40%
Drug Development
38%
Diabetes Mellitus
33%
Atrial Fibrillation
33%
Biological Product
31%
Drug Utilization
30%
Antidepressant
29%
QT Prolongation
29%
Observational Study
28%
Cross-Sectional Study
27%
Heart Arrhythmia
27%
Prevalence
25%
Insulin Analog
25%
Selective Serotonin Reuptake Inhibitor
22%
Non Insulin Dependent Diabetes Mellitus
20%
Dabigatran
17%
Drug Safety
17%
Bleeding
17%
Ankylosing Spondylitis
17%
Diseases
17%
Adverse Event
17%
Colorectal Carcinoma
16%
Apixaban
16%
Rivaroxaban
16%
Clinical Trial
15%
Chemotherapy
15%
Clinical Trial Design
14%
Human Insulin
14%
Recombinant Human Insulin
14%
Non-Steroidal Anti-Inflammatory Drug
14%
Antivitamin K
14%
Cross Sectional Study
13%
Calcium Channel Blocker
13%
Femur Fracture
13%
Chronic Obstructive Lung Disease
13%
Biosimilar Agent
13%
Case-Control Study
12%
Metformin
11%
Standardized Incidence Ratio
11%
Randomized Controlled Trial
11%
Ischemic Heart Disease
11%
Liver Injury
11%
Insulin Glargine
10%
Orphan Drug
10%
Medicine and Dentistry
Cohort Analysis
83%
Cancer Risk
59%
Breast Cancer
57%
Hodgkin's Lymphoma
56%
Meta-Analysis
40%
Systematic Review
37%
Diabetes Mellitus
32%
Radiation Therapy
32%
Malignant Neoplasm
29%
Maturity Onset Diabetes of the Young
29%
Medicine
25%
Hazard Ratio
25%
Diabetes
23%
Cancer Incidence
21%
Colorectal Carcinoma
21%
Atrial Fibrillation
18%
Ankylosing Spondylitis
17%
Direct Oral Anticoagulant
17%
Major Bleeding
17%
Chronic Obstructive Pulmonary Disease
17%
Antidiabetic Agent
14%
Cohort Effect
14%
Bladder Cancer
14%
Vitamin K Antagonist
14%
Prevalence
13%
Gastrointestinal Cancer
13%
Pharmacovigilance
13%
Retrospective Cohort Study
13%
Standardized Incidence Ratio
13%
Recombinant Human Insulin
13%
Human Insulin
13%
Breast Tumor
13%
Advanced Therapy
13%
Incretin
13%
Out of Hospital Cardiac Arrest
13%
Proportional Hazards Model
12%
Patient with Diabetes
12%
Adverse Drug Reaction
12%
Decision Making
12%
Procarbazine
11%
Cross Sectional Study
11%
Adverse Event
11%
Case-Control Study
11%
Glycon
11%
Drug Safety
10%
Insulin Treatment
10%
General Medicine
10%
QTc Interval
10%
Neoplasm
9%
Diseases
9%
